ReviewFrontiers in cell and developmental biology2026
Non-coding RNA-driven cardiovascular immunometabolic reprogramming: from inflammatory endotypes to therapeutic opportunities.
Review in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular disease is increasingly recognized as a heterogeneous immunometabolic disorder shaped by inflammation, metabolic rewiring, endothelial dysfunction, mitochondrial stress, and tissue remodeling across diverse cell types. This review provides a hypothesis-generating conceptual synthesis of non-coding RNA-driven cardiovascular immunometabolic reprogramming from an inflammatory endotype-oriented perspective. Because ncRNA profiling has not yet prospectively assigned cardiovascular patient cohorts to validated inflammatory endotypes, we frame mechanism-based endotypes as complementary research constructs rather than clinically deployable diagnostic categories. We discuss how conventional disease labels, including atherosclerosis, myocardial infarction, heart failure, hypertension, and cardiomyopathy, may be cross-mapped to dominant mechanisms such as athero-inflammation, sterile ischemic injury, fibro-inflammatory remodeling, metabolic inflammation, and vascular immune-endothelial dysfunction. We summarize how microRNAs, long non-coding RNAs, circular RNAs, and extracellular vesicle-associated RNA species regulate macrophage cholesterol handling, inflammasome activation, endothelial activation, vascular smooth muscle cell plasticity, cardiomyocyte mitochondrial dysfunction, fibroblast activation, extracellular matrix remodeling, and intercellular communication, with added attention to circRNA tissue-source patterns in cardiac, immune-cell, endothelial, and vascular compartments. We also highlight their context-dependent and cell type-specific actions, which challenge simple protective-versus-pathogenic classifications. Finally, we discuss translational opportunities, including circulating and extracellular vesicle-associated non-coding RNAs as liquid biopsy candidates, RNA-based therapeutics, endotype-enriched study designs, and traditional medicine-inspired multicomponent strategies. Despite barriers related to delivery, specificity, disease stage, species conservation, analytical standardization, and validation, integrated phenotyping, multi-omics profiling, functional perturbation, and biomarker-enriched trials may advance non-coding RNAs as candidate classifiers, regulators, markers, and therapeutic targets in precision cardiovascular medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.